

**Ongoing Disclosure Notice** 

# **Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	24 July 2024
Date of last disclosure:	15 July 2024

### Director or senior manager giving disclosure

Full name(s):	
Name of listed issuer:	
Name of related body corporate (if applicable):	
Position held in listed issuer:	

24 July 2024	
15 July 2024	

Lyndal Jane York Fisher & Paykel Healthcare Corporation Limited Chief Financial Officer

# Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest

### For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

9	,653 Ordinary Shares
9	,653 Ordinary Shares
L	yndal Jane York & Alexander Eric York
L	yndal Jane York & Alexander Eric York

### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

### Details of affected derivative-

he notional value of the derivative (if any) or the notional amount of underlying roducts (if any):	financial
statement as to whether the derivative is cash settled or physically settled:	
laturity date of the derivative (if any):	
xpiry date of the derivative(if any):	
he price specified in the terms of the derivative (if any):	
ny other details needed to understand how the amount of the consideration pa nder the derivative or the value of the derivative is affected by the value of the nderlying financial products:	
or that derivative,-	
arties to the derivative:	
the director or senior manager is not a party to the derivative, the nature of the terest in the derivative:	e relevant

acqui sp

Total number of transactions to which notice relates:

# Two

### Details of transactions requiring disclosure-

Date of transaction:

(a) 7 July 2023 (b) 28 February 2022 

 Nature of transaction:

 Name of any other party or parties to the transaction (if known):

 The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

### Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

### Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

## Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

(a) Correction of disclosure dated 21 July 2023 to reflect that 9 Ordinary Shares were issued under the Company's dividend reinvestment plan, as opposed to the 8 Ordinary Shares that were disclosed.


(b) Clarification of total number of Ordinary Shares held, including a beneficial interest in 71 Ordinary Shares issued to a trustee under an Employee Share Scheme, as disclosed on 7 March 2022.

Nil

(a) 1 Ordinary Share(b) 71 Ordinary Shares

(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
(a) Beneficial
(b) Beneficial

(a) 159,843 Options
(b) 75,306 Performance Share Rights
(a) Lyndal Jane York
(b) Lyndal Jane York



0.0		

# 24 July 2024 Raelene Leonard, Company Secretary